Investment
Features
FeesSafety
Academy
More
Pluang+

Bitfinex received over $100 million in USDT from an unknown wallet, signaling major stablecoin movement.

Market News
20 Oct 2026
Tokenpost
View Source
Neutral
Bitfinex received over $100 million in USDT from an unknown wallet, signaling major stablecoin movement.

On October 20, Bitfinex, a major cryptocurrency exchange, received a transfer of 100,980,000 Tether (USDT) worth approximately $100.9 million from an unidentified wallet. Such large stablecoin transfers are closely watched because USDT is widely used for trading and liquidity in crypto markets. This significant inflow to Bitfinex could indicate increased trading activity or liquidity adjustments, making it important for traders monitoring stablecoin flows. The source of the transfer remains unknown, adding an element of uncertainty to the market implications.

Bitfinex's receipt of 100.98 million USDT from an unidentified wallet provides context for crypto market watchers. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 03:41 WIB: out of 50 major cryptocurrencies priced on Pluang, 45 rose and 4 fell today. Notable movers include MANA (Decentraland) at Rp1.569 with a 4.74% increase and a Pluang order activity of 87% Sell / 13% Buy, XTZ (Tezos) at Rp5.654 with a 4.65% rise and 67% Sell / 33% Buy order activity, and BAT (Basic Attention Token) at Rp3.601 with a 4.63% gain and 84% Sell / 16% Buy order activity.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
1 hour ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
2 hours ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App